{"id":2763,"date":"2009-12-08T17:48:34","date_gmt":"2009-12-08T16:48:34","guid":{"rendered":"https:\/\/www.rcts.fr\/uncategorized\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of"},"modified":"2020-04-07T16:14:19","modified_gmt":"2020-04-07T14:14:19","slug":"achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of","status":"publish","type":"post","link":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/","title":{"rendered":"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL)"},"content":{"rendered":"<p><span>Arthritis&amp;Rheum.2009;60(10 suppl):S669(P1786)<\/span><\/p>\n<p><span>M Dougados, B Combe, J Braun, R Landew\u00e9, J Sibilia, A Cantagrel, V Leblanc, I Logeart<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Arthritis&amp;Rheum.2009;60(10 suppl):S669(P1786) M Dougados, B Combe, J Braun, R Landew\u00e9, J Sibilia, A Cantagrel, V Leblanc, I Logeart<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[66],"class_list":["post-2763","post","type-post","status-publish","format-standard","hentry","category-rheumatology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL) - RCTs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL) - RCTs\" \/>\n<meta property=\"og:description\" content=\"Arthritis&amp;Rheum.2009;60(10 suppl):S669(P1786) M Dougados, B Combe, J Braun, R Landew\u00e9, J Sibilia, A Cantagrel, V Leblanc, I Logeart\" \/>\n<meta property=\"og:url\" content=\"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"2009-12-08T16:48:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-07T14:14:19+00:00\" \/>\n<meta name=\"author\" content=\"Didier Not\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Didier Not\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/#article\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/\"},\"author\":{\"name\":\"Didier Not\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\"},\"headline\":\"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL)\",\"datePublished\":\"2009-12-08T16:48:34+00:00\",\"dateModified\":\"2020-04-07T14:14:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/\"},\"wordCount\":56,\"commentCount\":0,\"publisher\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#organization\"},\"articleSection\":[\"Rheumatology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/\",\"name\":\"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL) - RCTs\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#website\"},\"datePublished\":\"2009-12-08T16:48:34+00:00\",\"dateModified\":\"2020-04-07T14:14:19+00:00\",\"breadcrumb\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rcts.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL)\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"http:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\",\"name\":\"Didier Not\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"caption\":\"Didier Not\"},\"url\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/dnorcts-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL) - RCTs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/","og_locale":"en_US","og_type":"article","og_title":"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL) - RCTs","og_description":"Arthritis&amp;Rheum.2009;60(10 suppl):S669(P1786) M Dougados, B Combe, J Braun, R Landew\u00e9, J Sibilia, A Cantagrel, V Leblanc, I Logeart","og_url":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/","og_site_name":"RCTs","article_published_time":"2009-12-08T16:48:34+00:00","article_modified_time":"2020-04-07T14:14:19+00:00","author":"Didier Not","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Didier Not"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/#article","isPartOf":{"@id":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/"},"author":{"name":"Didier Not","@id":"http:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5"},"headline":"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL)","datePublished":"2009-12-08T16:48:34+00:00","dateModified":"2020-04-07T14:14:19+00:00","mainEntityOfPage":{"@id":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/"},"wordCount":56,"commentCount":0,"publisher":{"@id":"http:\/\/www.rcts.fr\/#organization"},"articleSection":["Rheumatology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/","url":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/","name":"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL) - RCTs","isPartOf":{"@id":"http:\/\/www.rcts.fr\/#website"},"datePublished":"2009-12-08T16:48:34+00:00","dateModified":"2020-04-07T14:14:19+00:00","breadcrumb":{"@id":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/www.rcts.fr\/en\/achievement-of-a-patient-acceptable-symptom-state-pass-and-of-a-minimum-clinically-important-improvement-mcii-with-etanercept-in-refractory-heel-enthesitis-related-to-spondyloarthritis-results-of\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rcts.fr\/"},{"@type":"ListItem","position":2,"name":"Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL)"}]},{"@type":"WebSite","@id":"http:\/\/www.rcts.fr\/#website","url":"http:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"http:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"http:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"http:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"http:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"http:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"http:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"http:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5","name":"Didier Not","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","caption":"Didier Not"},"url":"http:\/\/www.rcts.fr\/en\/author\/dnorcts-fr\/"}]}},"_links":{"self":[{"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=2763"}],"version-history":[{"count":1,"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2763\/revisions"}],"predecessor-version":[{"id":2765,"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2763\/revisions\/2765"}],"wp:attachment":[{"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=2763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=2763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}